Feedback / Questions
REX-8756 - Recludix Pharma
https://www.dermatologytimes.com/view/recludix-pharma-advances-first-in-class-oral-stat6-inhibitor-rex-8756-for-inflammatory-diseases-including-atopic-dermatitis
Jun 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next